Wolwo Bio-Pharmaceutical (300357.SZ) announced that it has obtained a Drug Clinical Trial Approval Notice from the National Medical Products Administration's government service portal, approving the company's clinical trial application for S01D tablets.
The drug is intended for the treatment of drug-resistant pulmonary tuberculosis in adults.
The approval of this clinical trial application marks a significant research and development milestone for the company in the field of anti-drug-resistant tuberculosis drugs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments